---
title: "Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer | LTRN Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288422476.md"
description: "Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer | LTRN Stock News"
datetime: "2026-06-02T04:15:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288422476.md)
  - [en](https://longbridge.com/en/news/288422476.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288422476.md)
generator: "portal-rs"
---

# Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer | LTRN Stock News

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer | LTRN Stock News

### Related Stocks

- [LTRN.US](https://longbridge.com/en/quote/LTRN.US.md)

## Related News & Research

- [LTRN: OMAI spun out, clinical pipeline advanced, and Q2 operating loss fell 25% year-over-year](https://longbridge.com/en/news/295929109.md)
- [LTRN: Net loss increased to $10.4M, with going concern risk and new AI subsidiary launched](https://longbridge.com/en/news/295928556.md)
- [04:03 ETDizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026](https://longbridge.com/en/news/296585269.md)
- [Is Harmonic (HLIT) Undervalued As Raised 2026 Broadband Guidance Meets A Quarterly Loss?](https://longbridge.com/en/news/296863161.md)
- [Harmonic (HLIT) Is Down 10.4% After Selling Video Unit And Raising Broadband Guidance Has The Bull Case Changed?](https://longbridge.com/en/news/296687443.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**